Genetesis Stock

genetesis.com/Healthcare / BioTech & PharmaFounded: 2013

Genetesis is a biopharma company focusing on the treatment of heart diseases and chest pain using digital and electric imaging technology. Genetesis has developed its Cardioflux imaging device, in which a patient can pass through, and by using magnetocardiography, it can pick up natural magnetic signals produced in the heart for optimal treatment and diagnosis options. Genetesis partners with healthcare organizations to bring its devices to the patients that could benefit from this type of cardiac care.

Register for Details

For more details on financing and valuation for Genetesis, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Genetesis.

Register Today

Genetesis investors also invested in these private companies

Mithril Capital Mangement
Ohio Innovation Fund
JobsOhio Growth Capital Fund
CincyTech

Team

Management Team

Peeyush Shrivastava
Co-Founder & Chief Executive Officer
Vineet Erasaia
Co-Founder & Chief Operations Officer
Emmanuel Setegn
Co-Founder & Chief Technology Officer
John Emanuel
Chief Financial Officer
Robert Takla
Chief Medical Officer

Board Members

John Rice, PhD
CincyTech
Anil Achyuta, PhD
TDK Ventures
Sajid Malhotra
Limelight Networks
Bill Baumel
Ohio Innovation Fund
Mark Cuban
Independent Director

Other companies like Genetesis in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Genetesis Announces Close of $17.5 Million Series C Financing
Genetesis, the market leader in next-generation biomagnetic imaging, has announced that it has closed $17.5 million in Series C Financing. The round was led by Mithril Capital with participation from Cercano Management as well as from existing investors, including JobsOhio Growth Capital, Ohio Innovation Fund and CincyTech
Updated on: Sep 24, 2023